Key Highlight
Max Healthcare's strong QoQ and YoY growth is overshadowed by an elevated P/E ratio, suggesting potential overvaluation despite bullish analyst sentiment and positive institutional shifts.
Snapshot
Summary
The market exhibits a bullish trend with prices above key EMAs, though the P/E ratio indicates potential overvaluation.
The company shows positive quarter-over-quarter and year-over-year growth in revenue and net profit.
Analyst ratings are predominantly positive, with a strong 'Buy' or 'Strong Buy' consensus, showing stability over time.
Institutional investors (FIIs and DIIs) collectively hold a significant majority of the company's shares, with a recent reallocation between them.
News highlights include sector-level updates on counterfeit drugs and trade pacts, which are not company-specific catalysts.
Latest News
- Counterfeit drugs: Why they remain a growing problem in India
- India, Russia-led bloc agree on key FTA chapter; SME and IPR talks advance
Price & Volume
The market is showing a bullish trend alignment with a score of 3.
The current price is above the 9-day, 21-day, and 50-day Exponential Moving Averages (EMAs).
The Relative Strength Index (RSI) is at 54.6, indicating a neutral momentum.
The price is trading within the Bollinger Bands, with the price position at 39.33% of the band width.
The Price-to-Earnings (P/E) ratio is currently 147.5, which is above its 6-month average and at the 81.75th percentile for the past 6 months.
Technicals
The market is exhibiting a bullish trend alignment, with the price trading above key moving averages. Momentum is neutral as indicated by the RSI. While the price is within the Bollinger Bands, the P/E ratio is elevated and at a high percentile compared to its 6-month average, suggesting potential overvaluation concerns. The P/B ratio is slightly above its 6-month average but at a more moderate percentile.
Fundamentals
The latest quarter (Mar 2026) reported revenue of ₹2,143 Cr and net profit of ₹342 Cr.
Quarter-over-quarter, revenue increased by 3.627%, net profit by 13.621%, and EPS by 13.916%.
Year-over-year, revenue saw a growth of 12.199%, net profit increased by 7.21%, and EPS grew by 7.317%.
Profit before tax showed a QoQ increase of 27.397% and a YoY increase of 15.672%.